Updated:
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a clinical-stage biotech developing Alzheimer's therapeutics including AL001, a vaccine candidate in Phase II trials.
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. was founded as a biotechnology company pursuing treatments for Alzheimer's disease, a neurodegenerative disorder affecting millions globally. The firm's origins are tied to intellectual property licensed from the University of South Florida and other research institutions, positioning it within the competitive CNS therapeutics landscape. The company's strategy centers on developing AL001, a vaccine candidate designed to target the amyloid-beta protein associated with Alzheimer's pathology. Alzamend also explores additional pipeline programs including AL002 and AL003, which focus on neuroinflammation and tau protein aggregation. The firm operates through a traditional biotech model, advancing internal candidates while seeking partnerships for later-stage development and commercialization. Alzamend Neuro had fewer than 50 full-time employees as of its most recent public filings (per SEC filings, 2024). The company operates primarily from its Tampa, Florida headquarters. A notable recent operational event: in January 2024, Alzamend announced initiation of a Phase II clinical trial for AL001 (per company press release, January 2024). A structural differentiator is Alzamend's reliance on out-licensing and collaboration agreements rather than building a fully integrated drug development infrastructure. This capital-efficient model allows the firm to advance multiple candidates while limiting operational burn—a strategy common among micro-cap biotechs but distinct from larger Alzheimer's-focused firms with extensive in-house capabilities.
General information
Firm type
Other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Alzamend Neuro?
Alzamend Neuro is led by a management team including CEO and Chairman Stephan Jackman (per SEC filings, 2024). The firm's board of directors oversees strategic direction, with clinical development decisions guided by the chief medical officer and scientific advisors. Investment in R&D is managed through board-approved budgets rather than an investment committee.
How does Alzamend Neuro fund its operations?
Alzamend Neuro funds its clinical programs through a combination of equity offerings, warrant exercises, and R&D collaborations (per SEC filings, 2024). The firm is publicly traded on Nasdaq under the ticker ALZN, allowing it to raise capital through primary and secondary offerings. Licensing income from partnerships is limited at this stage.
What investment stages does Alzamend Neuro typically target?
As a clinical-stage biotech, Alzamend Neuro targets internal development programs at Phase I through Phase II clinical stages. The firm does not invest in external companies; its sole investment activity is funding its own pipeline. This differs from family office structures that allocate capital across multiple external managers or direct deals.
Is Alzamend Neuro structured as a family office or a biotech company?
Alzamend Neuro is a publicly traded biotechnology corporation (Nasdaq: ALZN). It does not operate as a family office, asset manager, or investment vehicle. The firm's sole purpose is drug development, and its activities are regulated by the SEC and FDA. This makes it distinct from the family office classification.
What is Alzamend Neuro's known posture on partnerships or collaborations?
Alzamend Neuro pursues collaborations and licensing agreements to advance its pipeline. In March 2023, the firm entered into a research collaboration with the University of South Florida (per company press release, March 2023). The company's broader strategy involves out-licensing its candidates to larger pharmaceutical partners for later-stage development and commercialization, though no major partnership has been announced to date.
Where does the underlying wealth come from?
Alzamend Neuro is not a wealth-management entity; it is a publicly traded biotechnology firm funded by public and private investors. Consequently, there is no single family or individual whose wealth supports the operation—capital comes from institutional and retail shareholders.
Does Alzamend Neuro maintain philanthropic structures?
Alzamend Neuro does not operate philanthropic foundations or charitable arms. All resources are allocated to research and development activities. Any charitable donations are disclosed in SEC filings and are immaterial to the company's operations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: